Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Lunning

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Haematologica|October 19, 2023
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective studyAlexandra Rezazadeh, Aniko Szabo, Arushi Khurana, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Science Translational Medicine|June 21, 2019
Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphomaNeeraj Jain, Keenan Hartert, Saber Tadros, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Nature Communications|November 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSunandini Sharma, Roshia Ali, Alyssa Bouska, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Haematologica|October 19, 2023
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective studyAlexandra Rezazadeh, Aniko Szabo, Arushi Khurana, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Science Translational Medicine|June 21, 2019
Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphomaNeeraj Jain, Keenan Hartert, Saber Tadros, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Nature Communications|November 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSunandini Sharma, Roshia Ali, Alyssa Bouska, et al.
Haematologica|April 1, 2021
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphomaMan Chun John Ma, Saber Tadros, Alyssa Bouska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Pageof 7